Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination
Abstract Background The COVIH study is a prospective coronavirus disease 2019 (COVID-19) vaccination study in 1154 people with HIV (PWH), of whom 14% showed reduced antibody levels after primary vaccination. We evaluated whether an additional vaccination boosts immune responses in these hyporesponde...
Uloženo v:
| Vydáno v: | The Journal of infectious diseases Ročník 227; číslo 5; s. 651 - 662 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Oxford University Press
01.03.2023
|
| Témata: | |
| ISSN: | 0022-1899, 1537-6613, 1537-6613 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Abstract
Background
The COVIH study is a prospective coronavirus disease 2019 (COVID-19) vaccination study in 1154 people with HIV (PWH), of whom 14% showed reduced antibody levels after primary vaccination. We evaluated whether an additional vaccination boosts immune responses in these hyporesponders.
Methods
The primary end point was the increase in antibodies 28 days after additional mRNA-1273 vaccination. Secondary end points included neutralizing antibodies, S-specific T-cell and B-cell responses, and reactogenicity.
Results
Of the 66 participants, 40 previously received 2 doses ChAdOx1-S, 22 received 2 doses BNT162b2, and 4 received a single dose Ad26.COV2.S. The median age was 63 years (interquartile range [IQR], 60–66), 86% were male, and median CD4+ T-cell count was 650/μL (IQR, 423–941). The mean S1-specific antibody level increased from 35 binding antibody units (BAU)/mL (95% confidence interval [CI], 24–46) to 4317 BAU/mL (95% CI, 3275–5360) (P < .0001). Of all participants, 97% showed an adequate response and the 45 antibody-negative participants all seroconverted. A significant increase in the proportion of PWH with ancestral S-specific CD4+ T cells (P = .04) and S-specific B cells (P = .02) was observed.
Conclusions
An additional mRNA-1273 vaccination induced a robust serological response in 97% of PWH with a hyporesponse after primary vaccination.
Clinical Trials Registration. EUCTR2021-001054-57-N.
An additional 100 µg mRNA-1273 vaccination substantially increased SARS-CoV-2 S1-specific binding antibody levels in people with HIV with a serological hyporesponse after a primary vaccination regimen. This response was observed regardless of the primary vaccination regimen or patient characteristics. |
|---|---|
| AbstractList | The COVIH study is a prospective coronavirus disease 2019 (COVID-19) vaccination study in 1154 people with HIV (PWH), of whom 14% showed reduced antibody levels after primary vaccination. We evaluated whether an additional vaccination boosts immune responses in these hyporesponders.
The primary end point was the increase in antibodies 28 days after additional mRNA-1273 vaccination. Secondary end points included neutralizing antibodies, S-specific T-cell and B-cell responses, and reactogenicity.
Of the 66 participants, 40 previously received 2 doses ChAdOx1-S, 22 received 2 doses BNT162b2, and 4 received a single dose Ad26.COV2.S. The median age was 63 years (interquartile range [IQR], 60-66), 86% were male, and median CD4+ T-cell count was 650/μL (IQR, 423-941). The mean S1-specific antibody level increased from 35 binding antibody units (BAU)/mL (95% confidence interval [CI], 24-46) to 4317 BAU/mL (95% CI, 3275-5360) (P < .0001). Of all participants, 97% showed an adequate response and the 45 antibody-negative participants all seroconverted. A significant increase in the proportion of PWH with ancestral S-specific CD4+ T cells (P = .04) and S-specific B cells (P = .02) was observed.
An additional mRNA-1273 vaccination induced a robust serological response in 97% of PWH with a hyporesponse after primary vaccination. Clinical Trials Registration. EUCTR2021-001054-57-N. The COVIH study is a prospective coronavirus disease 2019 (COVID-19) vaccination study in 1154 people with HIV (PWH), of whom 14% showed reduced antibody levels after primary vaccination. We evaluated whether an additional vaccination boosts immune responses in these hyporesponders.BACKGROUNDThe COVIH study is a prospective coronavirus disease 2019 (COVID-19) vaccination study in 1154 people with HIV (PWH), of whom 14% showed reduced antibody levels after primary vaccination. We evaluated whether an additional vaccination boosts immune responses in these hyporesponders.The primary end point was the increase in antibodies 28 days after additional mRNA-1273 vaccination. Secondary end points included neutralizing antibodies, S-specific T-cell and B-cell responses, and reactogenicity.METHODSThe primary end point was the increase in antibodies 28 days after additional mRNA-1273 vaccination. Secondary end points included neutralizing antibodies, S-specific T-cell and B-cell responses, and reactogenicity.Of the 66 participants, 40 previously received 2 doses ChAdOx1-S, 22 received 2 doses BNT162b2, and 4 received a single dose Ad26.COV2.S. The median age was 63 years (interquartile range [IQR], 60-66), 86% were male, and median CD4+ T-cell count was 650/μL (IQR, 423-941). The mean S1-specific antibody level increased from 35 binding antibody units (BAU)/mL (95% confidence interval [CI], 24-46) to 4317 BAU/mL (95% CI, 3275-5360) (P < .0001). Of all participants, 97% showed an adequate response and the 45 antibody-negative participants all seroconverted. A significant increase in the proportion of PWH with ancestral S-specific CD4+ T cells (P = .04) and S-specific B cells (P = .02) was observed.RESULTSOf the 66 participants, 40 previously received 2 doses ChAdOx1-S, 22 received 2 doses BNT162b2, and 4 received a single dose Ad26.COV2.S. The median age was 63 years (interquartile range [IQR], 60-66), 86% were male, and median CD4+ T-cell count was 650/μL (IQR, 423-941). The mean S1-specific antibody level increased from 35 binding antibody units (BAU)/mL (95% confidence interval [CI], 24-46) to 4317 BAU/mL (95% CI, 3275-5360) (P < .0001). Of all participants, 97% showed an adequate response and the 45 antibody-negative participants all seroconverted. A significant increase in the proportion of PWH with ancestral S-specific CD4+ T cells (P = .04) and S-specific B cells (P = .02) was observed.An additional mRNA-1273 vaccination induced a robust serological response in 97% of PWH with a hyporesponse after primary vaccination. Clinical Trials Registration. EUCTR2021-001054-57-N.CONCLUSIONSAn additional mRNA-1273 vaccination induced a robust serological response in 97% of PWH with a hyporesponse after primary vaccination. Clinical Trials Registration. EUCTR2021-001054-57-N. Abstract Background The COVIH study is a prospective coronavirus disease 2019 (COVID-19) vaccination study in 1154 people with HIV (PWH), of whom 14% showed reduced antibody levels after primary vaccination. We evaluated whether an additional vaccination boosts immune responses in these hyporesponders. Methods The primary end point was the increase in antibodies 28 days after additional mRNA-1273 vaccination. Secondary end points included neutralizing antibodies, S-specific T-cell and B-cell responses, and reactogenicity. Results Of the 66 participants, 40 previously received 2 doses ChAdOx1-S, 22 received 2 doses BNT162b2, and 4 received a single dose Ad26.COV2.S. The median age was 63 years (interquartile range [IQR], 60–66), 86% were male, and median CD4+ T-cell count was 650/μL (IQR, 423–941). The mean S1-specific antibody level increased from 35 binding antibody units (BAU)/mL (95% confidence interval [CI], 24–46) to 4317 BAU/mL (95% CI, 3275–5360) (P < .0001). Of all participants, 97% showed an adequate response and the 45 antibody-negative participants all seroconverted. A significant increase in the proportion of PWH with ancestral S-specific CD4+ T cells (P = .04) and S-specific B cells (P = .02) was observed. Conclusions An additional mRNA-1273 vaccination induced a robust serological response in 97% of PWH with a hyporesponse after primary vaccination. Clinical Trials Registration. EUCTR2021-001054-57-N. An additional 100 µg mRNA-1273 vaccination substantially increased SARS-CoV-2 S1-specific binding antibody levels in people with HIV with a serological hyporesponse after a primary vaccination regimen. This response was observed regardless of the primary vaccination regimen or patient characteristics. |
| Author | Bruns, Anke H W Bogers, Susanne Papageorgiou, Grigorios Branger, Judith Jongkees, Marlou J Rijnders, Bart J A Sigaloff, Kim C E Roukens, Anna H E den Hollander, Jan G Langebeek, Nienke Katsikis, Peter D Geers, Daryl Jochems, Simon P Berrevoets, Marvin A H Schippers, Emile F van der Valk, Marc Gommers, Lennert Ammerlaan, Heidi S M Soetekouw, Robert Mueller, Yvonne M Delsing, Corine E van Vonderen, Marit G A Bierman, Wouter F W Leyten, Eliane M S Rokx, Casper Hensley, Kathryn S GeurtsvanKessel, Corine H Brinkman, Kees de Vries, Rory D Huisman, Wesley |
| Author_xml | – sequence: 1 givenname: Marlou J orcidid: 0000-0002-9589-7281 surname: Jongkees fullname: Jongkees, Marlou J – sequence: 2 givenname: Daryl surname: Geers fullname: Geers, Daryl – sequence: 3 givenname: Kathryn S surname: Hensley fullname: Hensley, Kathryn S – sequence: 4 givenname: Wesley orcidid: 0000-0002-5699-7087 surname: Huisman fullname: Huisman, Wesley – sequence: 5 givenname: Corine H surname: GeurtsvanKessel fullname: GeurtsvanKessel, Corine H – sequence: 6 givenname: Susanne surname: Bogers fullname: Bogers, Susanne – sequence: 7 givenname: Lennert surname: Gommers fullname: Gommers, Lennert – sequence: 8 givenname: Grigorios surname: Papageorgiou fullname: Papageorgiou, Grigorios – sequence: 9 givenname: Simon P surname: Jochems fullname: Jochems, Simon P – sequence: 10 givenname: Jan G surname: den Hollander fullname: den Hollander, Jan G – sequence: 11 givenname: Emile F surname: Schippers fullname: Schippers, Emile F – sequence: 12 givenname: Heidi S M surname: Ammerlaan fullname: Ammerlaan, Heidi S M – sequence: 13 givenname: Wouter F W surname: Bierman fullname: Bierman, Wouter F W – sequence: 14 givenname: Marc surname: van der Valk fullname: van der Valk, Marc – sequence: 15 givenname: Marvin A H surname: Berrevoets fullname: Berrevoets, Marvin A H – sequence: 16 givenname: Robert surname: Soetekouw fullname: Soetekouw, Robert – sequence: 17 givenname: Nienke surname: Langebeek fullname: Langebeek, Nienke – sequence: 18 givenname: Anke H W surname: Bruns fullname: Bruns, Anke H W – sequence: 19 givenname: Eliane M S surname: Leyten fullname: Leyten, Eliane M S – sequence: 20 givenname: Kim C E surname: Sigaloff fullname: Sigaloff, Kim C E – sequence: 21 givenname: Marit G A surname: van Vonderen fullname: van Vonderen, Marit G A – sequence: 22 givenname: Corine E surname: Delsing fullname: Delsing, Corine E – sequence: 23 givenname: Judith surname: Branger fullname: Branger, Judith – sequence: 24 givenname: Peter D surname: Katsikis fullname: Katsikis, Peter D – sequence: 25 givenname: Yvonne M surname: Mueller fullname: Mueller, Yvonne M – sequence: 26 givenname: Rory D surname: de Vries fullname: de Vries, Rory D – sequence: 27 givenname: Bart J A surname: Rijnders fullname: Rijnders, Bart J A – sequence: 28 givenname: Kees surname: Brinkman fullname: Brinkman, Kees – sequence: 29 givenname: Casper surname: Rokx fullname: Rokx, Casper – sequence: 30 givenname: Anna H E surname: Roukens fullname: Roukens, Anna H E email: A.H.E.Roukens@lumc.nl |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36402141$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkb1PwzAQxS1URD9gZUQeYQj1V5N4jCqglSqoWihj5NgOuErsECdDJ_51UqUgpjvpfne6994YDKyzGoBrjO4x4nRqbK6Mn-6NkGyGz8AIz2gUhCGmAzBCiJAAx5wPwdj7PUKI0TC6AEMaMkQwwyPwvSzL1roPbY00zQG6HAoLE6VMY5wVBSw3z0mASUThNtlsg7nbBQTuhJTGiiMCjYVr7apCw3fTfMLFcndqDpWrta-c9RomeaNruK5NKerD__VLcJ6LwuurU52At8eH1_kiWL08LefJKuhkkSagKmSUZAxJKbEQRFDEUcZzxkMttZKSUaY4o1zinISZznOUMUUjRSIuopjTCbjt71a1-2q1b9LSeKmLQljtWp92AmMcxzGfdejNCW2zUqu06r9Of03rgLsecG31N8UoPQaS9oGkp0DoD7KKfz4 |
| CitedBy_id | crossref_primary_10_1371_journal_pone_0323792 crossref_primary_10_1016_j_ijid_2024_107110 crossref_primary_10_1038_s41598_024_58597_4 crossref_primary_10_1093_cid_ciae026 crossref_primary_10_1111_apm_13379 crossref_primary_10_1016_j_jmii_2024_02_004 crossref_primary_10_3389_fmed_2023_1275843 crossref_primary_10_1016_j_isci_2023_107959 crossref_primary_10_1097_QAD_0000000000003933 crossref_primary_10_1016_j_jvacx_2025_100719 crossref_primary_10_1186_s12967_024_05147_1 crossref_primary_10_1038_s43856_025_00799_6 crossref_primary_10_3389_fimmu_2023_1129651 crossref_primary_10_3389_fimmu_2025_1587688 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2022 The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. |
| Copyright_xml | – notice: The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2022 – notice: The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. |
| DBID | TOX CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/infdis/jiac451 |
| DatabaseName | Oxford Journals Open Access Collection Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: TOX name: Open Access资源_Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1537-6613 |
| EndPage | 662 |
| ExternalDocumentID | 36402141 10.1093/infdis/jiac451 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: ZonMw grantid: 10430072010008 |
| GroupedDBID | --- -DZ -~X ..I .2P .55 .GJ .I3 .XZ .ZR 08P 0R~ 123 1KJ 1TH 29K 2AX 2WC 36B 3O- 4.4 41~ 48X 53G 5GY 5RE 5VS 5WD 6.Y 70D 85S AABZA AACGO AACZT AAHBH AAHTB AAJKP AAJQQ AAMVS AANCE AAOGV AAPGJ AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWDT AAWTL AAYOK ABBHK ABDPE ABEJV ABEUO ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPEJ ABPLY ABPPZ ABPTD ABQLI ABQNK ABSAR ABSMQ ABTLG ABWST ABXSQ ABXVV ABZBJ ACFRR ACGFO ACGFS ACGOD ACMRT ACPQN ACPRK ACUFI ACUTJ ACUTO ACYHN ACZBC ADACV ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKPW AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFHKK AFIYH AFOFC AFSHK AFXAL AFXEN AFYAG AGINJ AGKEF AGKRT AGMDO AGQXC AGSYK AGUTN AHMBA AHXPO AI. AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APJGH APWMN AQDSO AQKUS AQVQM ATGXG AVNTJ AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BR6 BTRTY BVRKM BZKNY C45 CDBKE CS3 CZ4 D-I DAKXR DCCCD DIK DILTD DOOOF DU5 D~K EBS ECGQY EE~ EIHJH EJD EMOBN ENERS ESX F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HQ3 HTVGU HW0 HZ~ IH2 IOX IPSME J21 J5H JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JSODD JST KAQDR KBUDW KOP KQ8 KSI KSN L7B LSO LU7 M49 MBLQV MHKGH MJL ML0 MVM N4W N9A NEJ NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P0- P2P PAFKI PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TOX TR2 VH1 W2D W8F WH7 X7H X7M Y6R YAYTL YKOAZ YXANX ZE2 ZGI ZKG ZXP ~91 ABDFA ABGNP ABPQP ABVGC ADNBA AEMQT AHMMS AJNCP ALXQX CGR CUY CVF ECM EIF JXSIZ NPM 7X8 AHGBF AJBYB |
| ID | FETCH-LOGICAL-c452t-3d6432b40ccc1aa2a3090b9f496ecedcc434d9439c1f26beff0b4d37d279a7893 |
| IEDL.DBID | TOX |
| ISICitedReferencesCount | 15 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000911203900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0022-1899 1537-6613 |
| IngestDate | Sun Sep 28 08:39:32 EDT 2025 Thu Apr 03 06:59:58 EDT 2025 Tue Nov 26 05:59:59 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | COVID-19 HIV nonresponder SARS-CoV-2 vaccines additional dose |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c452t-3d6432b40ccc1aa2a3090b9f496ecedcc434d9439c1f26beff0b4d37d279a7893 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-5699-7087 0000-0002-9589-7281 |
| OpenAccessLink | https://dx.doi.org/10.1093/infdis/jiac451 |
| PMID | 36402141 |
| PQID | 2738188895 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_2738188895 pubmed_primary_36402141 oup_primary_10_1093_infdis_jiac451 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-03-01 |
| PublicationDateYYYYMMDD | 2023-03-01 |
| PublicationDate_xml | – month: 03 year: 2023 text: 2023-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The Journal of infectious diseases |
| PublicationTitleAlternate | J Infect Dis |
| PublicationYear | 2023 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| SSID | ssj0004367 |
| Score | 2.5015168 |
| Snippet | Abstract
Background
The COVIH study is a prospective coronavirus disease 2019 (COVID-19) vaccination study in 1154 people with HIV (PWH), of whom 14% showed... The COVIH study is a prospective coronavirus disease 2019 (COVID-19) vaccination study in 1154 people with HIV (PWH), of whom 14% showed reduced antibody... |
| SourceID | proquest pubmed oup |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 651 |
| SubjectTerms | 2019-nCoV Vaccine mRNA-1273 Ad26COVS1 Aged Antibodies, Neutralizing Antibodies, Viral BNT162 Vaccine ChAdOx1 nCoV-19 COVID-19 COVID-19 Vaccines Female HIV Infections Humans Male Middle Aged Prospective Studies SARS-CoV-2 Vaccination |
| Title | Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36402141 https://www.proquest.com/docview/2738188895 |
| Volume | 227 |
| WOSCitedRecordID | wos000911203900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3PT9VAEJ4gAcNFERWfClmJ1w3dH912jw2RQAKPF8DnuzXb3W2sia3hFZN38l93tlvQoAe9NE2TabfzTdJvOzPfALxXQqW80oKaIAMghUyoNtpSb7ivM2T4tRt0Zs-y6TRfLPRsFIte_iWFr8Uheto1y8MvjbFyaJZmaR4i-vpi8asDUqjsThec4RbiXp7xofmDPrY_6OTwWTl--h8L2oYnI3ckRQT7Gaz5dgc24zTJ1Q48Ph_z5M_hx2lo--gwOPBCvyJdTUxLCuea-OuPfL2cFpQhqSBXxeUVPermlJO5sWg-QEWalsyG4nLyqek_k5PT-XiyQsIe62o9KcKAcTKLghW_m7-Aj8cfro9O6DhqgeIr8J4Kh8yEVzKx1jJjuBGJTipdS6289c5aRNFpJC-W1VxVvq6TSjqROZ5pkyHneQnrbdf6V0BMmiuV6zCOKJHSKpP61FbMVik3iWfVBA4QgfJbXFsZk-CijE4tR6dO4N0dQCXGe0himNZ3t8sytBIx3LbrdAK7Ebn7ewklgwQce_0vj3gDW2F0fKwnewvr_c2t34MN-71vljf78Chb5Hiczs73h1D7CbMszyA |
| linkProvider | Oxford University Press |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunogenicity+of+an+Additional+mRNA-1273+SARS-CoV-2+Vaccination+in+People+With+HIV+With+Hyporesponse+After+Primary+Vaccination&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Jongkees%2C+Marlou+J&rft.au=Geers%2C+Daryl&rft.au=Hensley%2C+Kathryn+S&rft.au=Huisman%2C+Wesley&rft.date=2023-03-01&rft.pub=Oxford+University+Press&rft.issn=0022-1899&rft.eissn=1537-6613&rft.volume=227&rft.issue=5&rft.spage=651&rft.epage=662&rft_id=info:doi/10.1093%2Finfdis%2Fjiac451&rft.externalDocID=10.1093%2Finfdis%2Fjiac451 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon |